These tools will no longer be maintained as of December 31, 2024. Archived website can be found here. PubMed4Hh GitHub repository can be found here. Contact NLM Customer Service if you have questions.


BIOMARKERS

Molecular Biopsy of Human Tumors

- a resource for Precision Medicine *

96 related articles for article (PubMed ID: 8851645)

  • 1. Risperidone use in a teaching hospital during its first year after market approval: economic and clinical implications.
    Carter CS; Mulsant BH; Sweet RA; Maxwell RA; Coley K; Ganguli R; Branch R
    Psychopharmacol Bull; 1995; 31(4):719-25. PubMed ID: 8851645
    [TBL] [Abstract][Full Text] [Related]  

  • 2. Using antipsychotic agents in older patients.
    Alexopoulos GS; Streim J; Carpenter D; Docherty JP;
    J Clin Psychiatry; 2004; 65 Suppl 2():5-99; discussion 100-102; quiz 103-4. PubMed ID: 14994733
    [TBL] [Abstract][Full Text] [Related]  

  • 3. Oral versus injectable antipsychotic treatment in early psychosis: post hoc comparison of two studies.
    Emsley R; Oosthuizen P; Koen L; Niehaus DJ; Medori R; Rabinowitz J
    Clin Ther; 2008 Dec; 30(12):2378-86. PubMed ID: 19167596
    [TBL] [Abstract][Full Text] [Related]  

  • 4. [Prescribing patterns of antipsychotics in 13 French psychiatric hospitals].
    Bret P; Bret MC; Queuille E
    Encephale; 2009 Apr; 35(2):129-38. PubMed ID: 19393381
    [TBL] [Abstract][Full Text] [Related]  

  • 5. [Long-acting injectable risperidone: naturalistic study in three hospitals in Aquitaine].
    Raignoux C; Dusouchet T; Bret P; Queuille E; Biscay ML; Caron J; Bret MC
    Encephale; 2007 Dec; 33(6):973-81. PubMed ID: 18789790
    [TBL] [Abstract][Full Text] [Related]  

  • 6. Management of agitation, aggression, and psychosis associated with dementia: a pooled analysis including three randomized, placebo-controlled double-blind trials in nursing home residents treated with risperidone.
    De Deyn PP; Katz IR; Brodaty H; Lyons B; Greenspan A; Burns A
    Clin Neurol Neurosurg; 2005 Oct; 107(6):497-508. PubMed ID: 15922506
    [TBL] [Abstract][Full Text] [Related]  

  • 7. Risperidone in acute and long-term therapy of schizophrenia--a clinical profile.
    Pajonk FG
    Prog Neuropsychopharmacol Biol Psychiatry; 2004 Jan; 28(1):15-23. PubMed ID: 14687852
    [TBL] [Abstract][Full Text] [Related]  

  • 8. [Risperidone in the treatment of psychotic patients with opiate abuse and dependence].
    Casas M; Gutiérrez M; Gibert J; Bobes J; Roncero C; Octavio I
    Actas Esp Psiquiatr; 2001; 29(6):380-5. PubMed ID: 11730575
    [TBL] [Abstract][Full Text] [Related]  

  • 9. Economic outcomes of antipsychotic agents in a Medicaid population: traditional agents vs. risperidone.
    Nightengale BS; Crumly JM; Liao J; Lawrence BJ; Jacobs EW
    Psychopharmacol Bull; 1998; 34(3):373-82. PubMed ID: 9803771
    [TBL] [Abstract][Full Text] [Related]  

  • 10. Risperidone use at a state hospital: a clinical audit 2 years after the first wave of risperidone prescriptions.
    Chengappa KN; Sheth S; Brar JS; Parepally H; Marcus S; Gopalani A; Palmer A; Baker RW; Schooler NR
    J Clin Psychiatry; 1999 Jun; 60(6):373-8. PubMed ID: 10401915
    [TBL] [Abstract][Full Text] [Related]  

  • 11. Risperidone for the treatment of behavioral and psychological symptoms of dementia.
    Tune LE
    J Clin Psychiatry; 2001; 62 Suppl 21():29-32. PubMed ID: 11584986
    [TBL] [Abstract][Full Text] [Related]  

  • 12. An open, randomized, comparative study of efficacy and safety of risperidone and haloperidol in schizophrenia.
    Tamrakar SM; Nepal MK; Koirala NR; Sharma VD; Gurung CK; Adhikari SR
    Kathmandu Univ Med J (KUMJ); 2006; 4(2):152-60. PubMed ID: 18603890
    [TBL] [Abstract][Full Text] [Related]  

  • 13. Risperidone: clinical outcome predictors and cost-effectiveness in a naturalistic setting.
    Finley PR; Sommer BR; Corbitt JL; Brunson GH; Lum BL
    Psychopharmacol Bull; 1998; 34(1):75-81. PubMed ID: 9564202
    [TBL] [Abstract][Full Text] [Related]  

  • 14. Effectiveness of antipsychotic therapy in a naturalistic setting: a comparison between risperidone, perphenazine, and haloperidol.
    Coley KC; Carter CS; DaPos SV; Maxwell R; Wilson JW; Branch RA
    J Clin Psychiatry; 1999 Dec; 60(12):850-6. PubMed ID: 10665632
    [TBL] [Abstract][Full Text] [Related]  

  • 15. Pharmacogenetics of risperidone therapy in autism: association analysis of eight candidate genes with drug efficacy and adverse drug reactions.
    Correia CT; Almeida JP; Santos PE; Sequeira AF; Marques CE; Miguel TS; Abreu RL; Oliveira GG; Vicente AM
    Pharmacogenomics J; 2010 Oct; 10(5):418-30. PubMed ID: 19997080
    [TBL] [Abstract][Full Text] [Related]  

  • 16. The influence of side effect of antipsychotic on the course of treatment in adolescent.
    Graovac M; Ruzić K; Rebić J; Dadić-Hero E; Francisković T
    Psychiatr Danub; 2010 Mar; 22(1):108-11. PubMed ID: 20305603
    [TBL] [Abstract][Full Text] [Related]  

  • 17. Side-effects of generic.
    Ruzić K; Medved P; Dadić-Hero E; Graovac M; Tatalović-Vorkapić S; Grzeta IR
    Psychiatr Danub; 2010 Mar; 22(1):99-101. PubMed ID: 20305600
    [TBL] [Abstract][Full Text] [Related]  

  • 18. Risperidone side effects.
    Edleman RJ
    J Am Acad Child Adolesc Psychiatry; 1996 Jan; 35(1):4-5. PubMed ID: 8567610
    [No Abstract]   [Full Text] [Related]  

  • 19. A naturalistic study of clinical use of risperidone.
    Binder RL; McNiel DE; Sandberg DA
    Psychiatr Serv; 1998 Apr; 49(4):524-6. PubMed ID: 9550245
    [TBL] [Abstract][Full Text] [Related]  

  • 20. New therapeutic agents marketed in 1993.
    Hussar DA
    Pa Med; 1994 May; 97(5):12-7. PubMed ID: 8036027
    [TBL] [Abstract][Full Text] [Related]  

    [Next]    [New Search]
    of 5.